^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    AHR inhibitor

    Related drugs:
    Associations
    News

    Trials

    Apply
    Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer (NCT05472506)
    Phase 1
    Ikena Oncology
    Withdrawn
    Last update posted :
    03/15/2024
    Initiation :
    03/01/2023
    Primary completion :
    04/01/2023
    Completion :
    04/01/2023
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • IK-175